NCT02166463 2026-03-17Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin LymphomaNational Cancer Institute (NCI)Phase 3 Active not recruiting600 enrolled 14 charts 1 FDA
NCT02981628 2026-02-23Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaChildren's Oncology GroupPhase 2 Recruiting80 enrolled 1 FDA
NCT01516580 2026-02-09Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk PatientsGustave Roussy, Cancer Campus, Grand ParisPhase 3 Completed482 enrolled 2 FDA